A large study of more than 1.2 million people in Israel shows that Pfizer's vaccine is 94% effective against symptomatic cases of Covid-19. This is excellent news that confirms the excellent results of the vaccine in clinical trials.
According to a study published this Wednesday in the New England Journal of Medicine, the vaccine jointly developed by Pfizer (United States) and BioNTech (Germany) is 94% effective against symptomatic cases of Covid-19. These very encouraging results are consistent with the announcement made by the two structures last November, suggesting that their vaccine was 95% effective in preventing infections, based on the preliminary results of their large-scale phase 3 trial. /P>
“The fact that vaccines have worked so well in the real world...really suggests that if the nations of the world can muster the will, we now have the means to put end COVID-19 forever “said Ben Neuman, a virologist at Texas A&M University who was not involved in the research.
In this experiment, carried out in Israel at Clalit Health Services between December 20, 2020 and February 1, 2021, approximately 1.2 million people were divided into equal groups of vaccinated and unvaccinated. Each vaccinated subject was matched with an unvaccinated "control" person with similar characteristics in terms of sex, age, but also comorbidities and place of residence.
By comparing the data from the two groups, the researchers then highlighted an effectiveness against symptomatic infections of 57% between 14 and 20 days after the first dose , then at 94% seven days after the second dose . Note that the effectiveness of the vaccine was relatively constant for all age groups with slightly lower results for people with comorbidities.
These results are all the more impressive since the English variant was already circulating in Israel at that time, according to the authors. The country, where 4.25 million people have already received their first dose, aims to vaccinate the entire population over the age of sixteen by the end of March.
In France, remember that general practitioners and those at work can administer the AstraZeneca/Oxford vaccine to people aged 50 to 64 with comorbidities since this Thursday, February 25.
